Bellevue Group AG Acquires 6.6% Stake in Viridian Therapeutics, Inc.

Bellevue Group AG, a Swiss-based financial institution, has filed a Schedule 13G indicating a new significant ownership position in Viridian Therapeutics, Inc. (VRDN). As of March 31, 2026, Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG (BAM AG), reported beneficial ownership of 6,726,144 shares of common stock. This position represents approximately 6.6% of the company's outstanding shares, based on a total of 102,458,094 shares. The filing was made jointly by Bellevue Group AG and BAM AG, with both entities sharing voting and dispositive power over the reported shares. The acquisition is characterized as being held in the ordinary course of business, without the intent to influence or change the control of the issuer. This filing marks an increase from a previous ownership level of 0.0%, establishing Bellevue as a major institutional shareholder in the Waltham, Massachusetts-based biotechnology firm. The reporting persons are regulated by the Swiss Financial Market Supervisory Authority (FINMA).